Purpose: To investigate the type and severity of acquired colour vision deficiencies (CVDs) in molecularly proven Stargardt disease (STD) and to establish whether a relationship exists between best-corrected visual acuity (BCVA) and full-field electroretinography (ffERG), and the degree of CVD. Methods: A retrospective, cross-sectional study of 73 patients with a molecularly proven diagnosis of STD, who underwent extensive colour vision evaluation, using pseudo-isochromatic and arrangement tests. Thirteen patients underwent Nagel anomaloscopy. Results: Normal colour vision was found in almost 20% of patients. Red/green (R/G) CVDs increased as BCVA declined. About 45% of all R/G CVDs were of the deutan type, although protan type CVDs became progressively apparent when moving from the high to the low BCVA group. An additional blue/yellow CVD was noted in about 25% of patients. In 10/13 patients, a pseudoprotanomaly was noted on anomaloscopy. Severe CVDs leading to scotopization were noted in patients with low BCVA and/or long-standing disease. No statistically significant differences in ERG results were found between groups with or without a CVD. Conclusions: The degree and type of colour vision deficiency in STD patients correlate better with BCVA than with ffERG results. The presence of specific CVDs may help to establish a diagnosis of STD. A battery of colour vision tests is required to properly evaluate CVDs in STD.

Keywords:
Colour vision and electrophysiological tests, Stargardt macular dystrophy, Acquired colour vision defect, Stargardt disease, Fundus flavimaculatus, Genetics
1.
Stargardt K: Über familiäre, progressive Degeneration in der Makulagegend des Auges. Albrecht Von Graefes Arch Ophthalmol 1909;71:534-550.
2.
Franceschetti A, François J: Fundus flavimaculatus (in French). Arch Ophtalmol Rev Gen Ophtalmol 1965;25:505-530.
3.
Franceschetti A (ed): Über tapeto-retinale Degenerationen im Kindesalter: Dritter Fortbildungs-Kurs der deutschen ophthalmologischen Gesellschaft, Hamburg 1962. Stuttgart, Sautter, 1963, pp 107-120.
4.
Allikmets R: A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet 1997;17:122.
5.
Klien BA, Krill AE: Fundus flavimaculatus. Clinical, functional and histopathologic observations. Am J Ophthalmol 1967;64:3-23.
6.
Hadden OB, Gass JD: Fundus flavimaculatus and Stargardt's disease. Am J Ophthalmol 1976;82:527-539.
7.
Aaberg TM: Stargardt's disease and fundus flavimaculatus: evaluation of morphologic progression and intrafamilial co-existence. Trans Am Ophthalmol Soc 1986;84:453-487.
8.
Lois N, Holder GE, Bunce C, Fitzke FW, Bird AC: Phenotypic subtypes of Stargardt macular dystrophy-fundus flavimaculatus. Arch Ophthalmol 2001;119:359-369.
9.
Eagle RC Jr, Lucier AC, Bernardino VB Jr, Yanoff M: Retinal pigment epithelial abnormalities in fundus flavimaculatus: a light and electron microscopic study. Ophthalmology 1980;87:1189-2000.
10.
Delori FC, Staurenghi G, Arend O, Dorey CK, Goger DG, Weiter JJ: In vivo measurement of lipofuscin in Stargardt's disease-fundus flavimaculatus. Invest Ophthalmol Vis Sci 1995;36:2327-2331.
11.
Von Ruckmann A, Fitzke FW, Bird AC: In vivo fundus autofluorescence in macular dystrophies. Arch Ophthalmol 1997;115:609-615.
12.
Fishman GA: Fundus flavimaculatus. A clinical classification. Arch Ophthalmol 1976;94:2061-2067.
13.
Noble KG, Carr RE: Stargardt's disease and fundus flavimaculatus. Arch Ophthalmol 1979;97:1281-1285.
14.
Moloney JB, Mooney DJ, O'Connor MA: Retinal function in Stargardt's disease and fundus flavimaculatus. Am J Ophthalmol 1983;96:57-65.
15.
Armstrong JD, Meyer D, Xu S, Elfervig JL: Long-term follow-up of Stargardt's disease and fundus flavimaculatus. Ophthalmology 1998;105:448-457; discussion 457-448.
16.
Fujinami K, Lois N, Davidson AE, Mackay DS, Hogg CR, Stone EM, Tsunoda K, Tsubota K, Bunce C, Robson AG, Moore AT, Webster AR, Holder GE, Michaelides M: A longitudinal study of Stargardt disease: clinical and electrophysiologic assessment, progression, and genotype correlations. Am J Ophthalmol 2013;155:1075-1088. e1013.
17.
Lois N, Halfyard AS, Bird AC, Holder GE, Fitzke FW: Fundus autofluorescence in Stargardt macular dystrophy-fundus flavimaculatus. Am J Ophthalmol 2004;138:55-63.
18.
Lois N, Holder GE, Fitzke FW, Plant C, Bird AC: Intrafamilial variation of phenotype in Stargardt macular dystrophy-fundus flavimaculatus. Invest Ophthalmol Vis Sci 1999;40:2668-2675.
19.
McBain VA, Townend J, Lois N: Progression of retinal pigment epithelial atrophy in Stargardt disease. Am J Ophthalmol 2012;154:146-154.
20.
Chen B, Tosha C, Gorin MB, Nusinowitz S: Analysis of autofluorescent retinal images and measurement of atrophic lesion growth in Stargardt disease. Exp Eye Res 2010;91:143-152.
21.
Fujinami K, Lois N, Mukherjee R, McBain VA, Tsunoda K, Tsubota K, Stone EM, Fitzke FW, Bunce C, Moore AT, Webster AR, Michaelides M: A longitudinal study of Stargardt disease: quantitative assessment of fundus autofluorescence, progression, and genotype correlations. Invest Ophthalmol Vis Sci 2013;54:8181-8190.
22.
Krill AE, Fishman GA: Acquired color vision defects. Trans Am Acad Ophthalmol Otolaryngol 1971;75:1095-1111.
23.
Mantyjarvi M, Tuppurainen K: Color vision in Stargardt's disease. Int Ophthalmol 1992;16:423-428.
24.
Pinckers A, Marre M: Basic phenomena in acquired colour vision deficiency. Doc Ophthalmol 1983;55:251-271.
25.
Stargardt K: Über familiäre Degeneration in der Makulagegend des Auges, mit und ohne psychische Störungen. Arch Psychiatr Nervenkr 1917;58:852.
26.
Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M: ISCEV standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 2009;118:69-77.
27.
McCulloch DL, Marmor MF, Brigell MG, Hamilton R, Holder GE, Tzekov R, Bach M: ISCEV standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 2015;130:1-12.
28.
Birch J: Clinical use of the American Optical Company (Hardy, Rand and Rittler) pseudoisochromatic plates for red-green colour deficiency. Ophthalmic Physiol Opt 1997;17:248-254.
29.
Cole BL, Lian KY, Lakkis C: The new Richmond HRR pseudoisochromatic test for colour vision is better than the Ishihara test. Clin Exp Optom 2006;89:73-80.
30.
Pokorny J, Smith VC, Verriest G, Pinckers A: Congenital and Acquired Colour Vision Defects. New York, Grune & Stratton, 1979.
31.
Uvijls A: Kleurenzien en kleurzinstoornissen voor de practici. ‘s Gravenhage, Kugler Publications, 1998.
32.
Birch J: Pass rates for the Farnsworth D15 colour vision test. Ophthalmic Physiol Opt 2008;28:259-264.
33.
Uvijls A, Leroy BP, Leys M, De Rouck A, Kestelyn P: A large field panel D-15 test for low vision patients. Bull Soc Belge Ophtalmol 1998;270:57-65.
34.
Jaakson K, Zernant J, Kulm M, Hutchinson A, Tonisson N, Glavac D, Ravnik-Glavac M, Hawlina M, Meltzer MR, Caruso RC, Testa F, Maugeri A, Hoyng CB, Gouras P, Simonelli F, Lewis RA, Lupski JR, Cremers FP, Allikmets R: Genotyping microarray (gene chip) for the ABCR (ABCA4) gene. Hum Mutat 2003;22:395-403.
35.
Fumagalli A, Ferrari M, Soriani N, Gessi A, Foglieni B, Martina E, Manitto MP, Brancato R, Dean M, Allikmets R, Cremonesi L: Mutational scanning of the ABCR gene with double-gradient denaturing-gradient gel electrophoresis (DG-DGGE) in Italian Stargardt disease patients. Hum Genet 2001;109:326-338.
36.
Stenirri S, Fermo I, Battistella S, Galbiati S, Soriani N, Paroni R, Manitto MP, Martina E, Brancato R, Allikmets R, Ferrari M, Cremonesi L: Denaturing HPLC profiling of the ABCA4 gene for reliable detection of allelic variations. Clin Chem 2004;50:1336-1343.
37.
Franceschetti A, François J, Babel J: Les hérédo-dégénérescences choriorétiniennes. Paris, Masson et Cie, 1963.
38.
Krill AE, Deutman AF: The various categories of juvenile macular degeneration. Trans Am Ophthalmol Soc 1972;70:220-245.
39.
Deutman A: The Hereditary Dystrophies of the Posterior Pole of the Eye. Springfield, Thomas, 1971.
40.
Rotenstreich Y, Fishman GA, Anderson RJ: Visual acuity loss and clinical observations in a large series of patients with Stargardt disease. Ophthalmology 2003;110:1151-1158.
41.
Birch J: Diagnosis of Defective Colour Vision, ed 2. Boston, Butterworth-Heinemann, 2001.
42.
Birch J: Efficiency of the Ishihara test for identifying red-green colour deficiency. Ophthalmic Physiol Opt 1997;17:403-408.
43.
Birch J, McKeever LM: Survey of the accuracy of new pseudoisochromatic plates. Ophthalmic Physiol Opt 1993;13:35-40.
44.
Birch J: Identification of red-green colour deficiency: sensitivity of the Ishihara and American Optical Company (Hard, Rand and Rittler) pseudo-isochromatic plates to identify slight anomalous trichromatism. Ophthalmic Physiol Opt 2010;30:667-671.
45.
Melamud A, Hagstrom S, Traboulsi E: Color vision testing. Ophthalmic Genet 2004;25:159-187.
46.
François J, Verriest G: On acquired deficiency of colour vision, with special reference to its detection and classification by means of the tests of Farnsworth. Vision Res 1961;1:201-219.
47.
Gelisken O, De Laey JJ: A clinical review of Stargardt's disease and/or fundus flavimaculatus with follow-up. Int Ophthalmol 1985;8:225-235.
48.
Grützner P: Typische erworbene Farbensinnstörungen bei heredodegenerativen Maculaleiden. Graefes Arch Clin Exp Ophthalmol 1961;163:99-116.
49.
Fonda G, Gardner LR: Characteristics and low vision corrections in Stargardt's disease - educational and vocational achievements enhanced by low vision corrections. Ophthalmology 1985;92:1084-1091.
50.
Pinckers A: La maladie de Stargardt. Ann Oculist 1971;204:1331-1346.
51.
Maia-Lopes S, Silva ED, Silva MF, Reis A, Faria P, Castelo-Branco M: Evidence of widespread retinal dysfunction in patients with Stargardt disease and morphologically unaffected carrier relatives. Invest Ophthalmol Vis Sci 2008;49:1191-1199.
52.
Hermes D, Roth A, Borot N: The two-equation method. II. Results in retinal and optic nerve disorders; in Drum B, Verriest G (eds): Colour Vision Deficiencies. IX Doc Ophthalmol Proc Ser 52. Dordrecht, Kluwer Academic Publishers, 1989, pp 325-337.
53.
Itabashi R, Katsumi O, Mehta MC, Wajima R, Tamai M, Hirose T: Stargardt's disease/fundus flavimaculatus: psychophysical and electrophysiologic results. Graefes Arch Clin Exp Ophthalmol 1993;231:555-562.
54.
François J, Verriest G: On acquired deficiency of colour vision with special reference to its detection and classification by the means of the test of Farnsworth. Vision Res 1961;1:201-219.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.